Tenaya Therapeutics Inc (TNYA)

Dec 20, 2024

Tenaya Therapeutics (NASDAQ:TNYA) Earns Buy Rating from Chardan Capital - Defense World

Dec 20, 2024

Dec 20, 2024

Tenaya Therapeutics (NASDAQ:TNYA) Earns “Buy” Rating from HC Wainwright - Defense World

Dec 20, 2024

Dec 19, 2024

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $17.33 Average PT from Brokerages - MarketBeat

Dec 19, 2024

Dec 19, 2024

Tenaya Therapeutics (NASDAQ: TNYA) Senior Vice President Chihiro Saito Resigns: 8-K Filing - Defense World

Dec 19, 2024

Dec 18, 2024

Tenaya Therapeutics stock backed by H.C. Wainwright on TN-401 safety and protein expression gains - Investing.com

Dec 18, 2024

Dec 18, 2024

Tenaya Therapeutics (NASDAQ:TNYA) Receives "Buy" Rating from Chardan Capital - MarketBeat

Dec 18, 2024

Dec 18, 2024

Tenaya Therapeutics (NASDAQ:TNYA) Given "Buy" Rating at HC Wainwright - MarketBeat

Dec 18, 2024

Dec 18, 2024

Tenaya Stock Crashes as Cardio Gene Therapy Delivers Underwhelming Early-Stage Data - BioSpace

Dec 18, 2024

Dec 18, 2024

Contrasting Tenaya Therapeutics (NASDAQ:TNYA) and Vaxart (NASDAQ:VXRT) - Defense World

Dec 18, 2024

Dec 18, 2024

Tenaya Therapeutics stock hits 52-week low at $1.49 By Investing.com - Investing.com Canada

Dec 18, 2024

Dec 17, 2024

Tenaya stock in selloff on gene therapy data (TNYA:NASDAQ) - Seeking Alpha

Dec 17, 2024

Dec 17, 2024

Tenaya Therapeutics announces executive departure - Investing.com

Dec 17, 2024

Dec 17, 2024

Tenaya Therapeutics stock hits 52-week low at $1.49 - Investing.com

Dec 17, 2024

Dec 17, 2024

Tenaya Therapeutics Reports Promising TN-201 Trial Results - TipRanks

Dec 17, 2024

Dec 17, 2024

Tenaya Therapeutics’ Senior VP Resigns for New Opportunity - TipRanks

Dec 17, 2024

Dec 17, 2024

Tenaya reports positive early data on heart gene therapy - Investing.com

Dec 17, 2024

Dec 17, 2024

Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy - GlobeNewswire

Dec 17, 2024

Dec 16, 2024

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 - The Manila Times

Dec 16, 2024

Dec 16, 2024

Tenaya Therapeutics to Unveil Groundbreaking Gene Therapy Data for Heart Disease Treatment - StockTitan

Dec 16, 2024

Dec 16, 2024

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 - GlobeNewswire

Dec 16, 2024

Dec 15, 2024

Fmr LLC Raises Stock Holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World

Dec 15, 2024

Dec 10, 2024

Tenaya Therapeutics' SWOT analysis: gene therapy stock faces pivotal catalysts - Investing.com

Dec 10, 2024

Dec 10, 2024

Jacobs Levy Equity Management Inc. Buys 226,466 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - MarketBeat

Dec 10, 2024

Dec 05, 2024

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stake Decreased by RA Capital Management L.P. - MarketBeat

Dec 05, 2024

Nov 28, 2024

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Short Interest Update - MarketBeat

Nov 28, 2024

Nov 27, 2024

Around the Helix: Cell and Gene Therapy Company Updates – November 27, 2024 - CGTLive™

Nov 27, 2024

Nov 26, 2024

First Patient Dosed in RIDGE-1 Trial for Tenaya’s ARV Cardiomyopathy Gene Therapy TN-401 - CGTLive™

Nov 26, 2024

Nov 26, 2024

Tenaya shares retain Buy rating, price target on trial update - Investing.com

Nov 26, 2024

Nov 25, 2024

Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase - GlobeNewswire

Nov 25, 2024

Nov 25, 2024

Tenaya Therapeutics Launches First-Ever PKP2-ARVC Gene Therapy Trial, Doses Initial Patient | TNYA Stock News - StockTitan

Nov 25, 2024

Nov 24, 2024

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $14.75 Average Target Price from Brokerages - MarketBeat

Nov 24, 2024

Nov 21, 2024

Tenaya Therapeutics Reports Q3 2024 Progress and Financial Results - TipRanks

Nov 21, 2024

Nov 19, 2024

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Nov 19, 2024

Nov 19, 2024

Tenaya Therapeutics Issues Stock Options to New Employees at $1.97 Per Share | TNYA Stock News - StockTitan

Nov 19, 2024

Nov 18, 2024

Tenaya Therapeutics SVP sells $4,786 in stock By Investing.com - Investing.com UK

Nov 18, 2024

Nov 18, 2024

Tenaya Therapeutics SVP sells $4,786 in stock - Investing.com

Nov 18, 2024

Nov 15, 2024

RA Capital Management's Strategic Acquisition in Tenaya Therapeu - GuruFocus.com

Nov 15, 2024

Nov 11, 2024

Research Analysts Offer Predictions for TNYA FY2024 Earnings - MarketBeat

Nov 11, 2024

Nov 11, 2024

Leerink Partnrs Issues Optimistic Estimate for TNYA Earnings - MarketBeat

Nov 11, 2024

Nov 11, 2024

William Blair Brokers Increase Earnings Estimates for TNYA - MarketBeat

Nov 11, 2024

Nov 10, 2024

Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) large institutional owners must be happy as stock continues to impress, up 42% over the past week - Simply Wall St

Nov 10, 2024

Nov 07, 2024

Tenaya Therapeutics (NASDAQ:TNYA) Price Target Lowered to $18.00 at Chardan Capital - MarketBeat

Nov 07, 2024

Nov 06, 2024

Latham Group, Inc. to Participate in the Baird 2024 Global Industrial Conference - The Manila Times

Nov 06, 2024

Nov 06, 2024

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Nov 06, 2024

Nov 05, 2024

abrdn plc Invests $1.06 Million in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - MarketBeat

Nov 05, 2024

Nov 04, 2024

BeyondSpring (BYSI) Stock Drops Amid Biotech Sector Volatility - GuruFocus.com

Nov 04, 2024

Nov 04, 2024

Beam Therapeutics (BEAM) Stock Surges with Strong Trading Volume - GuruFocus.com

Nov 04, 2024

Nov 03, 2024

Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance

Nov 03, 2024

Nov 01, 2024

Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation - Yahoo Finance

Nov 01, 2024

Oct 31, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Oct 31, 2024

Oct 30, 2024

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Oct 30, 2024